Interestingly, treatments for T2D already in place such as insulin, metformin, glucagon-like protein peptide-1 (GLP-1) receptor agonist and sodium-dependent glucose co-transporter SGLT-2 inhibitors have been known to have pleiotropic effects including anti-inflammatory consequences. Here, GLP1R is linked to type 2 diabetes mellitus.